CAR T-cell therapy is a treatment that re-engineers a patient’s T-cells with synthetic proteins called chimeric antigen receptors (CARs) which enhance the T-cell’s ability to recognise and kill cancer cells.

CAR T-cell therapy has proven effective in some diseases including B-cell malignancies, however, it is not effective in all patient populations.

CAR T-cell therapy continues to be a topic of ongoing clinical research nationally and internationally.

By the end of this rapid learning you will be able to:

  • explain how CAR T-cell therapy works to treat some cancers
  • identify the indications for CAR T-cell therapy
  • describe the CAR T-cell therapy clinical process
  • list common toxicities associated with CAR T-cell therapy and identify their signs and symptoms.

Viewing this on mobile? Tell us what you thought. Complete the survey

Module

CAR-T-cell-Start-1.png

 

Case study podcast

This Rapid  Listening, we hear from Erica Smeaton, National Nurse Manager at Lymphoma Australia who shares their experience with CAR T-cell therapy.  

 

Mini quiz 

Download the eviQ Education app to access exclusive content.

Use the QR code to access to CAR T-cell therapy mini quiz, or visit our mini quizzes homepage for more information.

qrcode-6.png

Resources

CAR T-cell therapy referral centres and contacts

Reference list

  • B-cell acute lymphoblastic leukaemia tisagenlecleucel 2020 V.1, eviQ Cancer Treatments Online, Cancer Institute NSW, viewed 16 Feb 2022, eviq.org.au/p/3832 
  • Diffuse large B-cell lymphoma tisagenlecleucel 2020 V.1, eviQ Cancer Treatments Online, Cancer Institute NSW, viewed 16 Feb 2022, eviq.org.au/p/3839
  • Chimeric antigen receptor (CAR) T-cell therapy, Lymphoma Australia, viewed 16 Feb 2022, https://www.lymphoma.org.au/about-lymphoma/treatments/targeted-therapy/chimeric-antigen-receptor-car-t-cell-therapy/
  • Maude, S.L., Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M.R., Stefanski, H.E., Myers, G.D. and Qayed, M., 2018. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), pp.439-448.
  • Schuster, S.J., Bishop, M.R., Tam, C.S., Waller, E.K., Borchmann, P., McGuirk, J.P., J├Ąger, U., Jaglowski, S., Andreadis, C., Westin, J.R. and Fleury, I., 2019. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine, 380(1), pp.45-56.
Create your own user feedback survey